Novartis Vaccines Unit Looks To Make Its Presence With New Technologies
Executive Summary
With a variety of new vaccines technology in play - such as cell-culture production, novel adjuvants and reverse vaccinology - Novartis' fledgling vaccines unit is at the cutting edge of vaccine development and could become a major player in the revitalized vaccine field
You may also be interested in...
Novartis Gets Bricks And Mortar Money: Last Vaccine Support From Bush Administration
Commercial production at North Carolina facility supported by the HHS grant is at least three years away.
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data